F2i

Indicaton

F2i is a first-in-class, non-kinase, protein-protein interaction inhibitor of aberrant fibroblast growth factor signalling pathway in invasive cancers

Therapeutic indications

Oncology

Type of product

Small molecule

Table

Phase

Discovery
Partnering status

Not partnered

You may also be interested in

MV-004

MV-004 is an orally available recombinant bacterial enzyme acting in the small intesine to adaptively modulate microbiota function during cancer immunotherapy. MV004 has been conceived to convert the majority of patients with solid tumors non-responding to immune checkpoint blockade (ICB) to responders.

Discovery

4D Lifetest Lung Dx, 4D Lifetest Breast Dx, 4D Lifetest Colon Dx

4D Lifetest Lung Dx is used as a verification assay to increase the overall sensitivity for the diagnosis of lung cancer for symptomatic patients in combination with other lung cancer specific diagnostics. 4D Lifetest Breast Dx is used as a verification assay to increase the overall sensitivity for the diagnosis of breast cancer for symptomatic patients in combination with other breat cancer specific diagnostics. 4D Lifetest Colon Dx is used as a verification assay to increase the overall sensitivity for the diagnosis of colon cancer for symptomatic patients in combination with other colon cancer specific diagnostics.

Marketed

TOP-N53, TOP-V122, TOP-M119 and TOP-N44

TOPADUR has discovered and developed new dual-acting drugs that target the cGMP-Enzyme Regulation System to stimulate microcirculation, enable tissue regeneration, and avoid local oxygen deficiency. Based on our key invention we have developed an attractive portfolio of drug candidates to treat aging-related diseases as chronic wounds, glaucoma, colorectal cancer, hair loss and skin aging.

Phase I started

F2i

Indicaton

Therapeutic indications

Type of product

Company

Table

You may also be interested in

MV-004

4D Lifetest Lung Dx, 4D Lifetest Breast Dx, 4D Lifetest Colon Dx

TOP-N53, TOP-V122, TOP-M119 and TOP-N44